Regulatory & Policy

Systematic, data-driven science coverage · Sunday, September 13, 2026
More from Regulatory & Policy
FDA consolidates cell and gene therapy development guidance
Regulatory & Policy

FDA consolidates cell and gene therapy development guidance

Category: Regulatory Policy | Regulatory Body: FDA/CBER | Geography: United States | Policy Instrument: Guidance document

Aug 20
FDA approves Regeneron’s Pasatru as second therapy for rare bone disease FOP
Regulatory & Policy

FDA approves Regeneron’s Pasatru as second therapy for rare bone disease FOP

The US FDA has approved Pasatru (garetosmab-grts), a fully human anti-Activin A monoclonal antibody developed by Regeneron Pharmaceuticals (Nasdaq: REGN),...

Aug 20
Teva's first-in-class Tourette drug filed for approval with FDA priority status
Regulatory & Policy

Teva's first-in-class Tourette drug filed for approval with FDA priority status

The US FDA has accepted Teva Pharmaceutical Industries' (NYSE: TEVA) New Drug Application for ecopipam (EBS-101), a selective dopamine D1 receptor...

Aug 20
FDA approves Genglycos as first gene therapy for glycogen storage disease type Ia
Regulatory & Policy

FDA approves Genglycos as first gene therapy for glycogen storage disease type Ia

The US FDA has granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), an AAV8 gene therapy developed by Novato, California-based...

Aug 20
858 Therapeutics' PARG inhibitor gets second fast-track award for breast cancer
Regulatory & Policy

858 Therapeutics' PARG inhibitor gets second fast-track award for breast cancer

San Diego-based 858 Therapeutics announced receipt of US FDA Fast Track Designation for ETX-19477, an oral poly(ADP-ribose) glycohydrolase (PARG) inhibitor,...

Aug 19
FDA seeks input on regulatory framework for generative AI-enabled medical devices
Regulatory & Policy

FDA seeks input on regulatory framework for generative AI-enabled medical devices

Category: Regulatory Policy | Regulatory Body: FDA | Geography: United States | Policy Instrument: Guidance document | Topics: AI in drug development ·...

Aug 19
Faeth's PIKTOR combo gets FDA fast track for biomarker-selected endometrial cancer
Regulatory & Policy

Faeth's PIKTOR combo gets FDA fast track for biomarker-selected endometrial cancer

Austin, Texas-based Faeth Therapeutics (Nasdaq: FTH) announced receipt of US FDA Fast Track Designation for sapanisertib and serabelisib (PIKTOR) in...

Aug 18
China moves quickly on ICH E6(R3) Annex 2 with March applicability date
Regulatory & Policy

China moves quickly on ICH E6(R3) Annex 2 with March applicability date

Category: Clinical Trial Reform | Regulatory Body: NMPA (CDE) | Geography: China | Instrument: Guidance document

Aug 17
The AllSci BriefFree, systematic R&D and deal news. Daily.
China NMPA sets framework for direct role in national R&D funding
Regulatory & Policy

China NMPA sets framework for direct role in national R&D funding

Category: Research Policy | Regulatory Body: NMPA (National Medical Products Administration) | Geography: China | Policy Instrument: Guidance document

Aug 17
US FDA approves Lantheus’ Tauklarify as second tau PET tracer for Alzheimer’s disease
Regulatory & Policy

US FDA approves Lantheus’ Tauklarify as second tau PET tracer for Alzheimer’s disease

The US FDA has approved Tauklarify (florquinitau F 18 injection, also known as MK-6240), a radiodiagnostic positron emission tomography (PET) agent for...

Aug 14
Biogen's felzartamab wins first global approval in China for multiple myeloma
Regulatory & Policy

Biogen's felzartamab wins first global approval in China for multiple myeloma

China's National Medical Products Administration (NMPA) has approved Jingshu (felzartamab), an anti-CD38 monoclonal antibody, in combination with...

Aug 14
Pfizer, Valneva Lyme vaccine enters EU review after Phase III
Regulatory & Policy

Pfizer, Valneva Lyme vaccine enters EU review after Phase III

The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the 6-valent outer surface protein A...

Aug 14
BMS scores first CELMoD approval as FDA embraces MRD surrogate
Regulatory & Policy

BMS scores first CELMoD approval as FDA embraces MRD surrogate

Bristol Myers Squibb has received US FDA accelerated approval for Zenbexus (iberdomide), the first cereblon E3 ligase modulating drug (CELMoD) to reach the...

Aug 14
Youcare takes Factor XI siRNA into US anticoagulation race
Regulatory & Policy

Youcare takes Factor XI siRNA into US anticoagulation race

China-based Youcare Pharmaceutical Group (SSE: 688658) received US FDA clearance to proceed with clinical trials of YKYY033 injection, a GalNAc-conjugated...

Aug 13
AC Immune takes Parkinson's vaccine into US trials as Phase II data near
Regulatory & Policy

AC Immune takes Parkinson's vaccine into US trials as Phase II data near

Switzerland-based AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company focused on neurodegenerative diseases, announced receipt of US FDA...

Aug 13